Royal Society of Biology

Karl Friston joins VERSES as Chief Scientist to Lead New Era in Artificial Intelligence

Retrieved on: 
Thursday, December 1, 2022

It is with great enthusiasm and excitement that we welcome Karl Friston to VERSES as our Chief Scientist, said Gabriel Ren, Founder, and CEO of VERSES.

Key Points: 
  • It is with great enthusiasm and excitement that we welcome Karl Friston to VERSES as our Chief Scientist, said Gabriel Ren, Founder, and CEO of VERSES.
  • Friston who was ranked #1 most influential neuroscientist in the world by Semantic Scholar in 2016 has had an illustrious and decorated scientific career.
  • I am genuinely delighted to be working alongside Karl Friston at VERSES, said Maxwell Ramstead, Director of Research at VERSES.
  • VERSES is a cognitive computing company specializing in next-generation Artificial Intelligence.

Emulate Announces Promotion of Dr. Lorna Ewart to Chief Scientific Officer

Retrieved on: 
Thursday, February 3, 2022

Emulate, Inc., a leading provider of next-generation in vitro models, today announced the promotion of Lorna Ewart, PhD, to Chief Scientific Officer.

Key Points: 
  • Emulate, Inc., a leading provider of next-generation in vitro models, today announced the promotion of Lorna Ewart, PhD, to Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220203005290/en/
    Emulate Announces Promotion of Dr. Lorna Ewart to Chief Scientific Officer (Photo: Business Wire)
    Dr. Ewart has played a pivotal role in expanding our organ model and application portfolio across brain physiology, inflammatory intestinal diseases, and toxicological assessmentall while leading our Cooperative Research and Development Agreement (CRADA) with the FDA, said Emulate CEO Jim Corbett.
  • Organ-on-a-chip technology can help us meet the need for more human-relevant predictive models to assess therapeutic modalities, said Dr. Ewart.
  • Being able to participate in the advancement of organ-chip technology and lead the scientific team at Emulate energizes me, said Dr. Ewart.

ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology

Retrieved on: 
Thursday, October 21, 2021

NEW YORK and LONDON, Oct. 21, 2021 /PRNewswire/ --ATP, a leader in life sciences venture capital, announced today the appointment of Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology.

Key Points: 
  • NEW YORK and LONDON, Oct. 21, 2021 /PRNewswire/ --ATP, a leader in life sciences venture capital, announced today the appointment of Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology.
  • Dr. Chopra also continues as a venture partner at ATP based in the firm's London office.
  • "We created the Head of Oncology role both to acknowledge the critical work Raj has been doing at ATP and to sharpen and amplify our oncology strategy.
  • "ATP's oncology strategy is to create flagship oncology companies in two ways," Dr. Chopra said.

ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology

Retrieved on: 
Thursday, October 21, 2021

NEW YORK and LONDON, Oct. 21, 2021 /PRNewswire/ --ATP, a leader in life sciences venture capital, announced today the appointment of Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology.

Key Points: 
  • NEW YORK and LONDON, Oct. 21, 2021 /PRNewswire/ --ATP, a leader in life sciences venture capital, announced today the appointment of Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology.
  • Dr. Chopra also continues as a venture partner at ATP based in the firm's London office.
  • "We created the Head of Oncology role both to acknowledge the critical work Raj has been doing at ATP and to sharpen and amplify our oncology strategy.
  • "ATP's oncology strategy is to create flagship oncology companies in two ways," Dr. Chopra said.

Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, August 25, 2021

Chardan Healthcare Acquisition 2 Corp. (CHAQ) previously announced on March 23, 2021 that it entered into a definitive merger agreement with Renovacor, Inc.

Key Points: 
  • Chardan Healthcare Acquisition 2 Corp. (CHAQ) previously announced on March 23, 2021 that it entered into a definitive merger agreement with Renovacor, Inc.
  • "Matt's extensive experience discovering, researching and developing AAV-based gene therapies for cardiovascular diseases makes him an ideal fit as Renovacor's CSO," said Magdalene Cook, M.D., chief executive officer of Renovacor.
  • About Chardan Healthcare Acquisition 2 Corp.
    CHAQ is a special purpose acquisition company formed for the purpose of effecting a merger, acquisition, or similar business combination.
  • Renovacor previously announced that it had entered into a merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purposes acquisition company.

Renovacor Announces the Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, August 25, 2021

Matts extensive experience discovering, researching and developing AAV-based gene therapies for cardiovascular diseases makes him an ideal fit as Renovacors CSO, said Magdalene Cook, M.D., chief executive officer of Renovacor.

Key Points: 
  • Matts extensive experience discovering, researching and developing AAV-based gene therapies for cardiovascular diseases makes him an ideal fit as Renovacors CSO, said Magdalene Cook, M.D., chief executive officer of Renovacor.
  • I am looking forward to working with the Renovacor team and its respected scientific and clinical advisors to build on these data as we seek to deliver transformative treatments to patients living with devastating diseases.
  • CHAQ intends to file a proxy statement, which will be sent to all CHAQ and Renovacor stockholders.
  • Neither Renovacor nor CHAQ gives any assurance that either Renovacor or CHAQ will achieve its expectations.